Marburg I polymorphism and the risk of venous thrombosis
FSAP nt 1601 . | Patients, no. (%) . | Controls, no. (%) . | OR . | 95% CI . |
|---|---|---|---|---|
| GG | 444 (94.3) | 441 (93.6) | 1* | NA |
| GA | 26 (5.5) | 28 (6.0) | 0.9 | 0.5-1.6 |
| AA | 1 (0.2) | 2 (0.4) | 0.5 | 0.05-5.5 |
| GA + AA | 27 (5.7) | 30 (6.4) | 0.9 | 0.5-1.5 |
FSAP nt 1601 . | Patients, no. (%) . | Controls, no. (%) . | OR . | 95% CI . |
|---|---|---|---|---|
| GG | 444 (94.3) | 441 (93.6) | 1* | NA |
| GA | 26 (5.5) | 28 (6.0) | 0.9 | 0.5-1.6 |
| AA | 1 (0.2) | 2 (0.4) | 0.5 | 0.05-5.5 |
| GA + AA | 27 (5.7) | 30 (6.4) | 0.9 | 0.5-1.5 |
There were 471 patients and 471 controls.
nt indicates nucleotide; NA, not applicable.
Reference category.